Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRX-801
- Development stage
- Phase 2
- Lead developer
- Mirum Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
MRX-801 is a drug candidate developed by ImaRx Therapeutics as an adjunctive therapy for acute ischemic stroke. It was evaluated in a Phase 1-2, randomized, placebo-controlled, single-blind, dose escalation study to assess its safety, tolerability, and activity when administered with continuous ultrasound as an adjunctive therapy to intravenous tissue plasminogen activator (tPA) treatment. The development of MRX-801 was effectively abandoned after ImaRx Therapeutics ceased operations and underwent a reverse merger.
- Brand names
- UNIPURE C3F8 Ophthalmic Gas
- Other names
- octafluoropropaneperfluoropropaneC3F8 gasC-3F8 gasC 3F8 gas
02
Targets
SLC10A2 (Solute carrier family 10 member 2)SLCO2B1 (Organic anion transporting polypeptide 2B1)
Beyond the preview
Go deeper on MRX-801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRX-801.